Meropenem Agmed (Meropenem Anhydrous)

Meropenem belongs to the carbapenem class and works by binding to penicillin‑binding proteins on bacterial cell walls. This inhibits the final step of peptidoglycan cross‑linking, weakening the wall and causing bacterial lysis. Its high affinity for multiple PBPs and resistance to most β‑lactamases give it a broad spectrum of activity.

The dosage of Meropenem Agmed is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare professionals calculate the appropriate dose and infusion rate to achieve optimal therapeutic levels while minimizing toxicity.

Safety data for meropenem in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers a broader activity against Pseudomonas aeruginosa and better stability against certain β‑lactamases. Its dosing flexibility and lower propensity for nephrotoxicity make it a preferred choice in many severe infections, though individual patient factors guide selection.

Meropenem Agmed should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. Proper cold‑chain storage maintains drug potency and ensures safety until reconstitution for intravenous administration.

Meropenem Agmed is supplied as a sterile powder for injection. It must be reconstituted with a suitable diluent and administered intravenously, usually over a 15‑30 minute infusion. The exact infusion rate and dosing schedule are determined by the prescribing clinician based on infection severity and patient-specific factors.

Serious risks include the potential for seizures, especially in patients with renal impairment or pre‑existing CNS disorders, and Clostridioides difficile‑associated colitis, which can be life‑threatening. Anaphylactic reactions and severe skin reactions such as Stevens‑Johnson syndrome are also rare but critical adverse events that require immediate medical attention.

Meropenem Agmed is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is advised for patients with a history of seizures, severe renal impairment, or those receiving valproic acid, as dose adjustments or alternative therapies may be necessary.